These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17466228)

  • 1. PROactive in patients with type 2 diabetes and previous myocardial infarction: swinging the sword of Damocles?
    Westerbacka J
    J Am Coll Cardiol; 2007 May; 49(17):1781-2. PubMed ID: 17466228
    [No Abstract]   [Full Text] [Related]  

  • 2. A perspective on coronary revascularization in the PROactive 05 study.
    Riche DM; Dale KM
    J Am Coll Cardiol; 2007 Oct; 50(17):1705-6; author reply 1706. PubMed ID: 17950157
    [No Abstract]   [Full Text] [Related]  

  • 3. The PROactive study: some answers, many questions.
    Yki-Järvinen H
    Lancet; 2005 Oct; 366(9493):1241-2. PubMed ID: 16214581
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Yin and the Yang of CV risks in patients with diabetes.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries CS; Russell-Jones DL
    BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies of diabetes, thiazolidinediones, and coronary heart disease.
    Walker AM; McAfee AT; Koro C
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1313-4; author reply 1314-6. PubMed ID: 18041104
    [No Abstract]   [Full Text] [Related]  

  • 11. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 12. Review article: Thiazolidinediones and heart failure.
    Chaggar PS; Shaw SM; Williams SG
    Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 14. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 15. PROactive study.
    Guillausseau PJ
    Lancet; 2006 Jan; 367(9504):23; author reply 26-7. PubMed ID: 16399140
    [No Abstract]   [Full Text] [Related]  

  • 16. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: the PROactive study--the glass is half full.
    Fonseca V; Jawa A; Asnani S
    J Clin Endocrinol Metab; 2006 Jan; 91(1):25-7. PubMed ID: 16303829
    [No Abstract]   [Full Text] [Related]  

  • 18. Setting the RECORD Straight.
    Nissen SE
    JAMA; 2010 Mar; 303(12):1194-5. PubMed ID: 20332408
    [No Abstract]   [Full Text] [Related]  

  • 19. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of rosiglitazone.
    Krall RL
    Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.